

Published in final edited form as:

Arch Intern Med. 2012 November 26; 172(21): 1678–1680. doi:10.1001/2013.jamainternmed.406.

The Promise of Primary Care–Based Screening for Diabetic Retinopathy: The Devil Will Be in the Details

Lauren Patty Daskivich, MD, MSHS and

Los Angeles County Department of Health Services, University of California, Los Angeles

Carol M. Mangione, MD, MSPH

Division of General Internal Medicine/Health Services Research, David Geffen School of Medicine, University of California, Los Angeles

Diabetes, a major cause of morbidity and mortality in the United States and the leading cause of new cases of blindness in adults, affects more than 25 million people, or 8.3% of the population.¹ Currently, only 60% of persons with diabetes receive standard-of-care screening examinations for retinopathy, and the number is even lower in the safety net.^{2, 3} Given that the projected increase in the prevalence of diabetes will increase the demand for screening examinations, we must identify alternative ways to screen for diabetic retinopathy (DR).

Primary care practitioners (PCPs) are frontline providers of diabetes care and, with the advent of the patient-centered medical home, a logical choice for an extension of specialty care services. The Research Letter in this issue of the *Archives* provides important evidence that fundus cameras designed to photograph the retina through an undilated pupil can be used effectively in primary care settings to screen for DR.⁴ As the authors note, most of the published data on primary care–based teleretinal DR screening in the United States have come from the robust program in the Veterans Health Administration.⁵ However, other large regional studies both in and out of the safety net (those health care providers who disproportionately care for the uninsured and publicly insured) have shown similar results.^{6, 7} While these studies certainly indicate that we may have found a strategy to rapidly increase screening for retinopathy, there are important issues that we must resolve to successfully move DR screening into the primary care setting.

Most importantly, we must avoid creating an unregulated cottage industry. Instead, we should strive for national standardization in the protocol and workflow processes from the outset, including use of a validated grading scale, furnishing reading centers with certified readers and ophthalmic oversight, and enabling seamless bidirectional communication between primary care and specialist providers through the use of electronic health records (EHRs). This standardization would both ensure the accuracy and reliability critical to fully

© 2012 American Medical Association. All rights reserved.

Correspondence: Dr Mangione, Barbara A. Levey & Gerald S. Levey Professor of Medicine and Health Services, University of California, Los Angeles, 10940 Wilshire Blvd, Ste 700, Los Angeles, CA 90024 (cmangione@mednet.ucla.edu).

Financial Disclosure: None reported.

Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

realizing the potential of this technology to prevent blindness and mitigate the risks associated with false-negative results.

We must insist on uniform reporting of results using an internationally accepted grading scale, such as the modified Airlie House classification established by the Early Treatment of Diabetic Retinopathy Study.⁸ Uniform reporting would allow us to move this technology to the standard expected for most diagnostic screening tests. As a diagnostic test, risk-stratified DR results can be reported with simple action-oriented response items for a busy PCP, similar to reports currently provided for mammograms and bone density scans. For teleretinal DR screening, the crux of the action item is the flagging of persons with diabetes who are in need of specialty eye care. This not only expedites care for those truly in need, improving clinical outcomes, but it also provides better understanding of the number of patients for whom specialty eye care is needed.

However, for health systems to accurately estimate the true need for specialty eye care, linking to a shared EHR and/or diabetic registry is crucial. This linkage enables data collection regarding diagnosis, follow-up, and treatments received. Obtaining this information is the only way we can truly understand the resources needed for efficient, high-quality workflow, cost, and long-term vision outcomes. In the era of EHR “meaningful use” stipulations by the US government, a seamless, transparent connection between primary and specialty care EHRs is not only feasible, it is essential if we are to decrease preventable blindness attributable to diabetes.

These data could also be useful in helping to target populations that may benefit the most from comprehensive, primary care–based screening. As noted in the Research Letter by Garg et al,⁴ racial and ethnic differences in prevalence and severity of DR exist. Importantly, however, previous research suggests that much of this difference is driven by associated risk factors such as socioeconomic status, education, and level of diabetic and/or hypertensive control. For these reasons, we might expect that patients in rural or urban resource-poor settings would have a higher prevalence and severity of DR identified at the time of initial screening than those in settings with greater resources. Latinos have been shown to have one of the highest rates of retinopathy among all safety-net groups,⁹ a difference that remains significant even after controlling for the aforementioned risk factors.¹⁰ Genetics has been posited as one reason for the difference in disease rates and severity, and studies are under way to investigate this. Whether it is socioeconomic status, health access, or genetics of the population served, there is a disproportionate burden of DR among those seen in the safety net. Many of these patients already have severe DR at their first screening eye examination; one safety-net study found that, on average, up to 12 years elapsed between diagnosis of diabetes and first retinopathy screening.¹¹

In addition to increasing opportunities for screening, patient education should not be overlooked as a contributor to low rates of initial presentation to eye care providers. Inadequate understanding of the disease and its processes is a formidable barrier for patients, since DR can be asymptomatic until very far progressed. Without comprehension of the risk of impending blindness, common problems for patients in underserved areas such as transportation and inability to take time off from work can make keeping eye appointments

difficult. Basing screening in primary care settings, where these patients are likely to present for a wide array of other medical concerns, will alleviate many of these logistical and cost barriers reported by patients.

Using teleretinal imaging to move screening for DR into the primary care arena has the potential to substantially reduce blindness among some of the most vulnerable persons in the US population. However, we must think before we act; we must recognize the fundamental necessity of standardization of these screening programs as we begin the implementation process, holding health care systems to the standard of care we have come to expect from diagnostic tests that guide primary care actions in other specialties. This standardization, combined with linkage to EHRs shared by primary care and specialty providers, holds promise for decreasing the large number of diabetic patients needlessly going blind from this treatable disease.

Acknowledgments

Funding/Support: Drs Daskivich and Mangione are supported in part by the UCLA Robert Wood Johnson Clinical Scholars Program and the US Department of Veterans Affairs (grant 67799). Dr Mangione received support from the Resource Centers for Minority Aging Research Center for Health Improvement of Minority Elderly under National Institutes of Health (NIH)/National Institute on Aging grant P30-AG021684, and from the NIH/National Center on Advancing Translational Sciences UCLA Clinical and Translational Science Institute grant No. UL1TR000124.

References

- Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA: US Dept of Health and Human Services, Centers for Disease Control and Prevention; 2011.
- National Committee for Quality Assurance. The State of Health Care Quality 2011 Report. <http://www.ncqa.org/tabid/836/Default.aspx>. Accessed July 18, 2012
- Wylie-Rosett J, Basch C, Walker EA, et al. Ophthalmic referral rates for patients with diabetes in primary-care clinics located in disadvantaged urban communities. *J Diabetes Complications*. 1995; 9(1):49–54. [PubMed: 7734744]
- Garg S, Jani PD, Kshirsagar AV, King B, Chaum E. Telemedicine and retinal imaging for improving diabetic retinopathy evaluation. *Arch Intern Med*. 2012; 172(21):1677–1678. [published online October 1, 2012]. [PubMed: 23026969]
- Conlin PR, Fisch BM, Orcutt JC, Hetrick BJ, Darkins AW. Framework for a national teleretinal imaging program to screen for diabetic retinopathy in Veterans Health Administration patients. *J Rehabil Res Dev*. 2006; 43(6):741–748. [PubMed: 17310423]
- Ogunyemi O, Terrien E, Eccles A, et al. Teleretinal screening for diabetic retinopathy in six Los Angeles urban safety-net clinics: initial findings. *AMIA Annu Symp Proc*. 2011; 2011:1027–1035. [PubMed: 22195163]
- Zimmer-Galler I, Zeimer R. Results of implementation of the DigiScope for diabetic retinopathy assessment in the primary care environment. *Telemed J E Health*. 2006; 12(2):89–98. [PubMed: 16620162]
- Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs: an extension of the modified Airlie House classification: ETDRS report number 10. *Ophthalmology*. 1991; 98 suppl(5):786–806. [PubMed: 2062513]
- Varma R, Torres M, Peña F, Klein R, Azen SP. Los Angeles Latino Eye Study Group. Prevalence of diabetic retinopathy in adult Latinos: the Los Angeles Latino Eye Study. *Ophthalmology*. 2004; 111(7):1298–1306. [PubMed: 15234129]

10. Harris MI, Klein R, Cowie CC, Rowland M, Byrd-Holt DD. Is the risk of diabetic retinopathy greater in non-Hispanic blacks and Mexican Americans than in non-Hispanic whites with type 2 diabetes? a US population study. *Diabetes Care*. 1998; 21(8):1230–1235. [PubMed: 9702425]
11. Appiah AP, Ganthier R Jr, Watkins N. Delayed diagnosis of diabetic retinopathy in black and Hispanic patients with diabetes mellitus. *Ann Ophthalmol*. 1991; 23(4):156–158. [PubMed: 2064260]